Cited by 166Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchGenetic Associations and Epidemiology

Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls

Open access
Bellenguez, Céline, Charbonnier, Camille, Grenier-Boley, Benjamin, Quenez, Olivier, Le Guennec, Kilan, Nicolas, Gaël, Chauhan, Ganesh, Wallon, David +81 more·2017·Neurobiology of Aging

Abstract

We performed whole-exome and whole-genome sequencing in 927 late-onset Alzheimer disease (LOAD) cases, 852 early-onset AD (EOAD) cases, and 1273 controls from France. We assessed the evidence for gene-based association of rare variants with AD in 6 genes for which an association with such variants was previously claimed. When aggregating protein-truncating and missense-predicted damaging variants, we found exome-wide significant association between EOAD risk and rare variants in SORL1, TREM2, and ABCA7. No exome-wide significant signal was obtained in the LOAD sample, and significance of the order of 10-6 was observed in the whole AD group for TREM2. Our study confirms previous gene-level results for TREM2, SORL1, and ABCA7 and provides a clearer insight into the classes of rare variants involved. Despite different effect sizes and varying cumulative minor allele frequencies, the rare protein-truncating and missense-predicted damaging variants in TREM2, SORL1, and ABCA7 contribute similarly to the heritability of EOAD and explain between 1.1% and 1.5% of EOAD heritability each, compared with 9.12% for APOE ε4.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2017.07.001

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SORL1 and ABCA7 carry numerous loss-of-function variants leading to strong increases in AD risk.

    “both SORL1 and ABCA7 genes—already detected by GWAS—carried numerous loss-of-function variants leading to strong increases in AD risk [9, 98, 128].”

    From The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? (2019) · cites this paper as [9]

    Sections 3.2 and 3.3 report numerous SORL1 and ABCA7 variants, and the Discussion reports elevated odds ratios for carriers of protein-truncating or strictly damaging variants in early-onset AD. But the paper only suggests that the damaging missense variants share a loss-of-function mechanism; it does not establish that all the counted variants are loss-of-function. It also says the association may be weaker in late-onset AD, so the unqualified claim about strong increases in AD risk overstates the finding. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Using a large whole-exome-sequencing study, ten genes located in genome-wide loci were identified as having rare deleterious coding, splicing or LOF burden associations with LOAD (FDR P < 0.01), including ABCA7, TREM2, SORL1, TREML4, TAP2, PSMB8, PIP, STYX, RIN3, and KCNH6.

    “we also identified ten genes located in our genome-wide loci as having rare deleterious coding, splicing or LOF burden associations with LOAD (false discovery rate (FDR) P < 0.01), including previously implicated rare-variant signals in ABCA7, TREM2, and SORL1 (refs. 14,49–55), and additional associations with TREML4 in the TREM2 locus, TAP2 and PSMB8 in the HLA-DRB1 locus, PIP in the EPHA1 locus,”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bellenguez, C., Charbonnier, C., Grenier-Boley, B., Quenez, O., Le Guennec, K., Nicolas, G., Chauhan, G., Wallon, D., Rousseau, S., Richard, A. C., Boland, A., Bourque, G., Munter, H. M., Olaso, R., Meyer, V., Rollin-Sillaire, A., Pasquier, F., Letenneur, L., Redon, R., Dartigues, J.-F., Tzourio, C., Frebourg, T., Lathrop, M., Deleuze, J.-F., Hannequin, D., Genin, E., Amouyel, P., Debette, S., Lambert, J.-C., Campion, D., Hannequin, D., Campion, D., Wallon, D., Martinaud, O., Zarea, A., Nicolas, G., Rollin-Sillaire, A., Bombois, S., Mackowiak, M.-A., Deramecourt, V., Pasquier, F., Michon, A., Le Ber, I., Dubois, B., Godefroy, O., Etcharry-Bouyx, F., Chauviré, V., Chamard, L., Berger, E., Magnin, E., Dartigues, J.-F., Auriacombe, S., Tison, F., Sayette, V. D. L., Castan, D., Dionet, E., Sellal, F., Rouaud, O., Thauvin, C., Moreaud, O., Sauvée, M., Formaglio, M., Mollion, H., Roullet-Solignac, I., Vighetto, A., Croisile, B., Didic, M., Félician, O., Koric, L., Ceccaldi, M., Gabelle, A., Marelli, C., Labauge, P., Jonveaux, T., Vercelletto, M., Boutoleau-Bretonnière, C., Castelnovo, G., Paquet, C., Dumurgier, J., Hugon, J., De Boisgueheneuc, F., Belliard, S., Bakchine, S., Sarazin, M., Barrellon, M.-O., Laurent, B., Blanc, F., Pariente, J., & Jurici, S.
Affiliations
  • Inserm (FR)
  • Université de Bordeaux (FR)
  • Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
  • McGill University and Génome Québec Innovation Centre (CA)
  • Centre National de la Recherche Scientifique (FR)
  • Centre Hospitalier Universitaire Amiens-Picardie (FR)
  • Centre National de Recherche en Génomique Humaine (FR)
  • Centre Hospitalier du Rouvray (FR)
  • Centre Hospitalier Universitaire de Montpellier (FR)
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2017-11
Volume
59
Pages
220.e1-220.e9
ISSN
0197-4580 (ISSN-L)
OpenAlex
W2735794637
Cited by
166
References
56
Citations by year
2026: 8 · 2025: 13 · 2024: 20 · 2023: 14 · 2022: 29 · 2021: 24 · 2020: 13 · 2019: 28 · 2018: 16
FWCI
11.53
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Aging (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • HAL (submittedVersion)
Funders
  • France Génomique National infrastructure
  • Centre National de Génotypage
  • National Foundation for Alzheimer's disease and related disorders
  • Institut Pasteur de Lille
  • Inserm
  • FRC
  • Lille Métropole Communauté Urbaine council
  • French government's LABEX
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
Alzheimer's disease, rare variants, TREM2, SORL1, ABCA7, early-onset Alzheimer's disease, late-onset Alzheimer's disease, truncating mutations, missense mutations, genetic risk, heritability, APOE ε4, gene-based association
MeSH terms
Whole Genome Sequencing, Adult, Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Membrane Glycoproteins, Middle Aged, Receptors, Immunologic, Genetic Variation, ATP-Binding Cassette Transporters, Genetic Predisposition to Disease, LDL-Receptor Related Proteins, Membrane Transport Proteins, Apolipoprotein E4, Genome-Wide Association Study, Young Adult, Genetic Association Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review